A Libtayo combo fails to beat Keytruda in first-line melanoma.
ApexOnco Front Page
Recent articles
Golcadomide and iberdomide are set to feature at EHA.
Unlike the US FDA, the CHMP doesn't recommend approval for pre-chemo prostate cancer.
The move shows a gap developing between Relay and Lilly in PI3Kα inhibition.
The Companion-002 trial of tovecimig fails to show an overall survival benefit versus chemo.
An anti-ER “Riptac” enters phase 1.
The company has started a pivotal trial of its KRAS G12D inhibitor in pancreatic cancer.
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
